Inflammatory bowel disease (IBD) is a general term for chronic or remitting/relapsing
inflammatory diseases of the intestinal tract and generally refers to ulcerative colitis (UC) …

Ulcerative colitis and Crohn's disease are the principal forms of inflammatory bowel disease.
Both represent chronic inflammation of the gastrointestinal tract, which displays …

Patients with inflammatory bowel disease (IBD) are at increased risk of thrombotic events.
Therapies for IBD have the potential to modulate this risk. The aims of this Evidence-Based …

Abstract Background and Aims This study aimed to compare real-world clinical effectiveness
and safety of vedolizumab, an α4β7-integrin inhibitor, and anti-tumour necrosis factor-α [anti …

The management of patients with moderate to severe inflammatory bowel disease was
transformed with the arrival of anti–tumor necrosis factor (TNF) therapy. Nevertheless, a …

She has no other significant medical or surgical history. Her current medications are
mesalamine 2.4 g/d and budesonide 9 mg/d. She appears thin and tired. Abdominal …

Ulcerative colitis (UC) is a chronic relapsing and remitting gastrointestinal disorder of
uncertain aetiology. The last two decades have seen an expansion in the therapeutic …

Background: About a third of patients with inflammatory bowel disease do not respond to
anti-tumour necrosis factor (anti-TNF) therapy, which is challenging. Aim: To review the …

The management of moderate to severe ulcerative colitis has undergone significant
changes over the past 15 years due to the regulatory approval of several new drugs. In …

Background Direct comparisons are lacking between vedolizumab and tumour necrosis
factor (TNF)‐antagonist therapy in Crohn's disease (CD). Aim To compare safety and …